Determination of Cytosol c-erbB-2 Protein in Breast Cancer by Sandwich Enzyme Immunoassay

Japanese Journal of Clinical Oncology

Volumn 28, Issue 2, 1998, Pages 92-96

  Imoto, Shigeru ^a   Ohkura, Hisanao ^b   Sugano, Kokichi ^b   Sasaki, Yasutsuna ^a   Ito, Kuniaki ^a   Igarashi, Tadahiko ^a   Ohtsu, Tomoko ^a   Fujii, Hirofumi ^a   Minami, Hironobu ^a   Hasebe, Takahiro ^c   Mukai, Kiyoshi ^c  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Breast cancer; c erbB 2; Enzyme immunoassay

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST DISEASE; BREAST TUMOR; CANCER STAGING; CHEMISTRY; CYTOSOL; ENZYME IMMUNOASSAY; FEMALE; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROGNOSIS;

BREAST DISEASES; BREAST NEOPLASMS; CYTOSOL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 0031989134     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/28.2.92     Document Type: Article

References (21)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987,235:177-82.
2. Tsuda H, Hirohashi S, Shimosato Y, Tanaka Y, Hirota T, Tsugane S, et al. Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients Jpn J Cancer Res 1990;81:327-32.
3. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993;11:1936-42.
4. Hartmann LC, Ingle JN, Wold LE, Farr GH Jr, Grill JP, Su JQ, et al. Prognostic value of c-erbB-2 overexpression in axillary lymph node positive breast cancer. Cancer 1994;74:2956-63.
5. Schönborn I, Zschiesche W, Spitzer E, Minguillon C, Mohner M, Ebeling K, et al. C-erbB-2 overexpression in primary breast cancer: independent prognostic factor in patients at high risk. Breast Cancer Res Treat 1994;29:287-95.
6. Vijver MJV, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-45.
7. Pierce LJ, Merino MJ, D'Angelo T, Barker EA, Gilbert L, Cowan KH, et al. Is c-erbB-2 a predictor for recurrent disease in early stage breast cancer? Int J Radiat Oncol Biol Phys 1993;28:395-403.
8. Zschiesche W, Schonborn I, Minguillon C, Spitzer E Significance of immunohistochemical c-erbB-2 product localization pattern for prognosis of primary human breast cancer. Cancer Lett 1994;81:89-94.
9. Sugano K, Kitajima M, Ishii M, Koyama H, Kasumi F, Demura R, et al. Clinical evaluation of erbB-2 protein in tissue extract using an enzyme immuno assay (erbB-2 EIA 'NICHIRET). Gan To Kagakuryohu 1994;21:1957-66 (in Japanese).
10. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. Cancer 1989:65:1794-1800.
11. Masuko T, Sugahara K, Kozono M, Otsuki S, Akiyama T, Yamamoto T, et al A murine monoclonal antibody that recognizes as extracellular domain of the human c-erbB-2 protooncogene product. Jpn J Cancer Res 1989;80:10-14.
12. Mori S, Mori Y, Mukaiyama T, Yamada Y, Sonobe Y, Matsushita H, et al. In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells. Jpn J Cancer Res 1990;81:489-94.
13. Maeda Y, Ogita M, Ikeda Y, Kikuchi K, Yamaguchi T. Evaluation of erbB-2 protein in tissue extract compared with other prognostic factors in human breast cancers. Nippon Rinsho Geka Gakkai Zasshi 1997;58:8-11 (in Japanese)
14. Narita T, Funahashi H, Satoh Y, Imai T, Takagi H. Quantitative analysis of c-erbB-2 protein in breast cancer tissue by enzyme immunoassay. Jpn J Clin Oncol 1994;24:74-8.
15. Watanabe T, Fukutomi T, Tsuda H, Adachi I, Nanasawa T, Yamamoto H, et al. Determination of c-erbB-2 protein in primary breast cancer tissue extract using an enzyme immunoassay. Jpn J Cancer Res 1993;84:1279-86.
16. Piffanelli A, Dittadi R, Catozzi L, Gion M, Capitanio G, Gelli MC, et al. Determination of erbB-2 protein in breast cancer tissues by different methods. Relationships with other biological parameters. Breast Cancer Res Treat 1996;37:267-76.
17. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human cancer cells. Oncogene 1995;10:2435-46.
18. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive breast cancer. N Engl J Med 1994;330:1260-6.
19. Jacquemier J, Penault-Llorca F, Viens P, Houvenaeghel G, Hassoun J, Torrente M, et al. Breast cancer response to adjuvant chemotherapy in correlation with erbB-2 and p53 expression. Anticancer Res 1994;14:2773-8.
20. Borg Å, Baldetorp B, Fernö M, Killander D, Olsson H, Rydén S, et al. ErbB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994;81:137-44.
21. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blarney RW, et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 1995;72:1259-66.